Lipoprotein and Apolipoproteins With Metabolic Liver Diseases

Disorders of Lipoprotein Metabolism and Other Lipidaemias Clinical Trial

Official title:

Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03220971
• Other study ID #: 1060603
• Status: Active, not recruiting
• First received: July 3, 2017
• Last updated: April 17, 2018
• Start date: September 20, 2017
• Est. completion date: October 2019

Study information

• Verified date: April 2018
• Source: Tainan Municipal Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Theranostic translation applications against viral, metabolic liver diseases and hepatic oncogenesis: lipoprotein and apolipoproteins at a crossroad

Description:

An intimate link between microbial infections, metabolic changes and oncogenesis has been drawn attentions increasingly, indicating a crossroad leading to pathogenesis and disease progression. Globally the burden of hepatitis B and C virus infections is 450 and 185 millions, respectively and chronic hepatitis disease causes a high risk of liver cirrhosis, hepatocellular carcinoma and metabolic disorders

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 440
• Est. completion date: October 2019
• Est. primary completion date: October 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

1. above 20 years

2. nonalcoholic fatty liver disease

3. Non-Alcoholic Steatohepatitis

Exclusion Criteria:

1. alcohonic hepatitis 2. Autoimmune liver disease 3. HIV postive

Related Conditions & MeSH terms

• Disorders of Lipoprotein Metabolism and Other Lipidaemias
• Hyperlipidemias
• Liver Diseases

Intervention

Other:
• lipoprotein and apolipoproteins
To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases

Locations

Country	Name	City	State
Taiwan	Chun-Hsiang Wang	Tainan

Sponsors (1)

Lead Sponsor	Collaborator
Chun-Hsiang Wang

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad	Study the interplay between hepatitis C virus (HCV) and lipid metabolism(the HCV infection affects host lipid homeostasis, regarding transportation, synthesis, and catabolism.)	2years